PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Delay = Buy Opportunity, page-22

  1. 478 Posts.
    lightbulb Created with Sketch. 66
    I Mean this smells....why on earth would PAR be asking for more than their P1 and P2 objectives in that it involves non clinical data....it doesn't make sense!!!

    "I am guessing that PAR are seeking a broader than we expected charter.If the non-clinical data is tied to either, then what is its nature, is it essential, what is its purpose, marketing material?"
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.